GCCL Strengthens Global Vaccine Collaboration with Bismederi at World Vaccine Congress 2026
On April 3, GCCL, a global clinical trial specimen analysis organization, announced that it had signed a memorandum of understanding (MOU) with Bismederi, a European bioanalysis specialist company, at the World Vaccine Congress 2026 (WVC 2026) held in Washington, D.C., United States.
This agreement aims to strengthen the foundation for cooperation connecting Europe and the Asia-Pacific (APAC) region in the field of vaccine development, leveraging the analytical expertise and regional networks both companies have accumulated. It is also intended to jointly explore new business opportunities in the global market. In particular, both companies plan to expand the scope of support for global vaccine development projects, including responses to emerging infectious diseases and pandemics, by linking their advanced BL2~3-level research facilities and vaccine and infectious disease analysis capabilities.
Joo Kwan-gu, CEO of GCCL, and Alessandro Manenti, CDO of Bismederi, are taking a commemorative photo after the vaccine cooperation MOU. GCCL
View original imageThe signing ceremony took place at WVC 2026, where global vaccine industry professionals gathered, serving as an opportunity to confirm the direction of cooperation between the two companies and discuss concrete measures for collaboration in the global vaccine development and clinical trial markets.
Through this agreement, the two companies will explore the possibility of collaborating on projects at various stages of development, including research on vaccine candidates based on high-risk pathogens. They also plan to expand cooperation in various areas such as joint marketing and project operation support.
In particular, by leveraging their respective regional strengths and expertise, the two companies plan to connect Europe's regulatory science expertise with Asia's efficient clinical infrastructure to provide global vaccine development clients with more systematic and integrated clinical trial analysis support services.
Alessandro Manenti, Chief Development Officer (CDO) of Bismederi, stated, "This MOU is an important milestone for strengthening the foundation of cooperation in the global vaccine development market, based on each company's vaccine analysis expertise and regional networks. We look forward to discovering new collaborative opportunities in various markets and expanding synergies in supporting vaccine development projects together with GCCL."
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
Jo Gwan-gu, CEO of GCCL, said, "Vaccine development requires an understanding of regional regulations and operational environments, as well as highly reliable analytical support. Through this agreement, we have further strengthened the foundation for global collaboration to respond to new variants and pandemic situations. Moving forward, by linking the expertise and networks of both companies, we will provide global vaccine development clients with more systematic and reliable services."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.